Gilead Sciences (Brazil) Today
| GILD34 Stock | BRL 273.00 2.87 1.04% |
Performance11 of 100
| Odds Of DistressLess than 9
|
Gilead Sciences is trading at 273.00 as of the 11th of January 2025, a 1.04 percent decrease since the beginning of the trading day. The stock's open price was 275.87. Gilead Sciences has less than a 9 % chance of experiencing financial distress in the next few years and had a good performance during the last 90 days. The performance scores are derived for the period starting the 12th of December 2024 and ending today, the 11th of January 2025. Click here to learn more.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. The company has 2.49 B outstanding shares. More on Gilead Sciences
Moving together with Gilead Stock
Moving against Gilead Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Gilead Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Gilead Sciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Gilead Sciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman of the Board, CEO | Daniel ODay |
| Business Concentration | Drug Manufacturers - Major, Healthcare (View all Sectors) |
Gilead Sciences (GILD34) is traded on Sao Paulo Exchange in Brazil and employs 31 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 572.2 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Gilead Sciences's market, we take the total number of its shares issued and multiply it by Gilead Sciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Gilead Sciences operates under Healthcare sector and is part of Drug Manufacturers - Major industry. The entity has 2.49 B outstanding shares.
Gilead Sciences has accumulated about 28.36 B in cash with 9.07 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 22.39.
Check Gilead Sciences Probability Of Bankruptcy
Gilead Sciences Risk Profiles
Although Gilead Sciences' alpha and beta are two of the key measurements used to evaluate Gilead Sciences' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.1 | |||
| Semi Deviation | 1.63 | |||
| Standard Deviation | 1.73 | |||
| Variance | 2.98 |
Gilead Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Gilead Sciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Gilead Sciences Corporate Management
Elected by the shareholders, the Gilead Sciences' board of directors comprises two types of representatives: Gilead Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Gilead. The board's role is to monitor Gilead Sciences' management team and ensure that shareholders' interests are well served. Gilead Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Gilead Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Johanna Mercier | Chief Commercial Officer | Profile | |
| Deborah Telman | Gen Affairs | Profile | |
| Jyoti Mehra | Ex HR | Profile | |
| Jacquie CFA | VP Relations | Profile | |
| Diane Wilfong | Corp VP | Profile |
Additional Information and Resources on Investing in Gilead Stock
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.